US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 02:46:12 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:My fiancé died on the morning of our wedding day
Next:Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
You may also like
- Pregnancy app used by the NHS accused of 'imposing gender ideology'
- Senior Chinese leaders attend deliberations at annual legislative session
- Wildfire destroys prized mushrooms, income source for Tibetans — Radio Free Asia
- Senior Chinese legislator emphasizes importance of handling ethnic affairs according to the law
- The government wants to buy their flood
- China urges U.S. to release details of bio
- Tennessee Vols wrap up spring practice with Nico Iamaleava finally under center
- China urges U.S. to release details of bio
- Auburn running back Brian Battie on ventilator after weekend shooting in Florida, coach says